These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1953 related articles for article (PubMed ID: 24559803)

  • 41. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
    Metser U; Even-Sapir E
    Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular imaging of malignant tumor metabolism: whole-body image fusion of DWI/CT vs. PET/CT.
    Reiner CS; Fischer MA; Hany T; Stolzmann P; Nanz D; Donati OF; Weishaupt D; von Schulthess GK; Scheffel H
    Acad Radiol; 2011 Aug; 18(8):940-6. PubMed ID: 21718953
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study.
    Iagaru A; Mittra E; Yaghoubi SS; Dick DW; Quon A; Goris ML; Gambhir SS
    J Nucl Med; 2009 Apr; 50(4):501-5. PubMed ID: 19289439
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnostic accuracy of whole-body diffusion-weighted magnetic resonance imaging with 3.0 T in detection of primary and metastatic neoplasms.
    Akay S; Kocaoglu M; Emer O; Battal B; Arslan N
    J Med Imaging Radiat Oncol; 2013 Jun; 57(3):274-82. PubMed ID: 23721135
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
    Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE
    Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does positron emission tomography data acquisition impact simultaneous diffusion-weighted imaging in a whole-body PET/MRI system?
    Buchbender C; Hartung-Knemeyer V; Heusch P; Heusner TA; Beiderwellen K; Wittsack HJ; Kühl H; Forsting M; Bockisch A; Antoch G; Lanzman RS
    Eur J Radiol; 2013 Feb; 82(2):380-4. PubMed ID: 23238361
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.
    Sommer G; Wiese M; Winter L; Lenz C; Klarhöfer M; Forrer F; Lardinois D; Bremerich J
    Eur Radiol; 2012 Dec; 22(12):2859-67. PubMed ID: 22772365
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
    Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
    Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
    Schmidt GP; Kramer H; Reiser MF; Glaser C
    Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Whole-body MRI, including diffusion-weighted imaging, for staging lymphoma: comparison with CT in a prospective multicenter study.
    Kwee TC; Vermoolen MA; Akkerman EA; Kersten MJ; Fijnheer R; Ludwig I; Beek FJ; van Leeuwen MS; Bierings MB; Bruin MC; Zsíros J; Quarles van Ufford HM; de Klerk JM; Adam J; Stoker J; Uiterwaal CS; Nievelstein RA
    J Magn Reson Imaging; 2014 Jul; 40(1):26-36. PubMed ID: 24307538
    [TBL] [Abstract][Full Text] [Related]  

  • 51. How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1 h: the Stanford Approach.
    Muehe AM; Theruvath AJ; Lai L; Aghighi M; Quon A; Holdsworth SJ; Wang J; Luna-Fineman S; Marina N; Advani R; Rosenberg J; Daldrup-Link HE
    Mol Imaging Biol; 2018 Apr; 20(2):324-335. PubMed ID: 28721605
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oncological whole-body staging in integrated (18)F-FDG PET/MR: Value of different MR sequences for simultaneous PET and MR reading.
    Schaarschmidt BM; Grueneisen J; Heusch P; Gomez B; Beiderwellen K; Ruhlmann V; Umutlu L; Quick HH; Antoch G; Buchbender C
    Eur J Radiol; 2015 Jul; 84(7):1285-92. PubMed ID: 25975895
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Magnetic resonance imaging of malignant lymphoma.
    Vermoolen MA; Kersten MJ; Fijnheer R; van Leeuwen MS; Kwee TC; Nievelstein RA
    Expert Rev Hematol; 2011 Apr; 4(2):161-71. PubMed ID: 21495926
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing central compartment neck dissection for squamous cell carcinoma of the larynx, hypopharynx, and esophagus.
    Kim JW; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2013 May; 49(5):449-53. PubMed ID: 23321549
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging.
    Brechtel K; Klein M; Vogel M; Mueller M; Aschoff P; Beyer T; Eschmann SM; Bares R; Claussen CD; Pfannenberg AC
    J Nucl Med; 2006 Mar; 47(3):470-6. PubMed ID: 16513616
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Three-way Comparison of Whole-Body MR, Coregistered Whole-Body FDG PET/MR, and Integrated Whole-Body FDG PET/CT Imaging: TNM and Stage Assessment Capability for Non-Small Cell Lung Cancer Patients.
    Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Seki S; Yui M; Yamagata H; Aoyagi K; Matsumoto S; Sugimura K
    Radiology; 2015 Jun; 275(3):849-61. PubMed ID: 25584709
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience.
    Komori T; Narabayashi I; Matsumura K; Matsuki M; Akagi H; Ogura Y; Aga F; Adachi I
    Ann Nucl Med; 2007 Jun; 21(4):209-15. PubMed ID: 17581719
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pediatric bone sarcoma: diagnostic performance of ¹⁸F-FDG PET/CT versus conventional imaging for initial staging and follow-up.
    Quartuccio N; Fox J; Kuk D; Wexler LH; Baldari S; Cistaro A; Schöder H
    AJR Am J Roentgenol; 2015 Jan; 204(1):153-60. PubMed ID: 25539251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 98.